<DOC>
	<DOCNO>NCT01209832</DOCNO>
	<brief_summary>The purpose study evaluate whether tasisulam act inducer CYP3A use midazolam sensitive specific probe substrate CYP3A . The study also assess safety tolerability tasisulam midazolam give combination document antitumor activity tasisulam .</brief_summary>
	<brief_title>A Tasisulam Midazolam Drug Interaction Study Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Midazolam</mesh_term>
	<criteria>Have histologically cytologically confirm solid malignancy lymphoma advance and/or metastatic disease respond standard therapy standard therapy exists . Have performance status less equal 2 Eastern Cooperative Oncology Group ( ECOG ) scale Have discontinue previous therapy cancer , include chemotherapy , radiotherapy , cancerrelated hormonal therapy , investigational therapy least 30 day ( 45 day mitomycinC nitrosoureas ) prior study enrollment recover acute effect therapy . Limited field radiotherapy permit ( consultation investigator ) Have estimate life expectancy , judgment investigator , great equal 12 week Have receive treatment within 30 day initial dose study drug experimental agent noncancer indication receive regulatory approval indication Have symptomatic central nervous system ( CNS ) malignancy metastasis ( screen require ) . Patients active brain metastasis exclude Have current acute chronic leukemia Patients clinically significant chronic obstructive pulmonary disease ( COPD ) respiratory disease may risk period conscious sedation midazolam Patients known history obstructive sleep apnea , difficult intubation , syndromes associate airway abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Metastatic Tumors</keyword>
	<keyword>Lymphoma</keyword>
</DOC>